Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) has provided an update.
NetraMark reported a pivotal quarter marked by an expanded contract backlog to approximately C$2.5 million, reflecting rising demand for its NetraAI clinical trial optimization platform and supporting its medium-term growth ambitions. The company completed onboarding as a technology partner with global CRO Worldwide Clinical Trials, enabling inclusion in Phase 2 and Phase 3 bids in CNS and oncology, and held a Critical Path Innovation Meeting with the U.S. FDA to discuss NetraAI’s role in predictive enrichment for clinical trial design, strengthening its regulatory and scientific positioning. NetraMark also secured acceptance of a peer-reviewed study on NetraAI in Nature Portfolio’s npj Digital Medicine, validating its explainable AI methodology in a Phase II depression trial, and, together with CAMH, won an Ontario Research Fund – Research Excellence Award to apply NetraAI to genetic and epigenetic data in schizophrenia and major depressive disorder, further enhancing its capabilities and credibility in psychiatric drug development.
More about NetraMark Holdings
NetraMark Holdings is a Toronto-based artificial intelligence company focused on transforming pharmaceutical clinical trials through its NetraAI platform, which uses explainable AI and precision analytics to optimize trial design, patient stratification, and treatment-response analysis, with a particular focus on central nervous system and oncology indications.
Average Trading Volume: 49,874
Technical Sentiment Signal: Hold
Current Market Cap: C$98.73M
See more data about AIAI stock on TipRanks’ Stock Analysis page.